Sonntag Johanna, Mannsperger Heiko, Jöcker Anika, Korf Ulrike
Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Methods Mol Biol. 2011;785:237-45. doi: 10.1007/978-1-61779-286-1_16.
To expedite the development of personalized medicine, new and reliable biomarkers are required to facilitate early diagnosis, to determine prognosis, predict response or resistance to different therapies, and to monitor disease progression or recurrence. Human body fluids, such as blood, present a promising resource for biomarker discovery, in every sense. Microspot immunoassays allow the simultaneous quantification of multiple analytes from a minute amount of samples in a single measurement. The experimental design of microspot immunoassays is based on antibody pairs recognizing different epitopes of the analyte. The first antibody is used to capture the analyte from the complex sample, and the second antibody is used for detection. As with traditional enzyme-linked immunosorbent assays, highly reliable and reproducible results are obtained.
为加速个性化医疗的发展，需要新的可靠生物标志物来促进早期诊断、确定预后、预测对不同疗法的反应或耐药性，以及监测疾病进展或复发。从各方面来看，人体体液（如血液）是发现生物标志物的一个有前景的资源。微斑点免疫测定法能够在单次测量中从微量样本同时定量多种分析物。微斑点免疫测定法的实验设计基于识别分析物不同表位的抗体对。第一种抗体用于从复杂样本中捕获分析物，第二种抗体用于检测。与传统酶联免疫吸附测定法一样，可获得高度可靠且可重复的结果。
